Research programme: dendritic cell vaccines - Argos/Kyowa Kirin
Alternative Names: eCD/IL-4Latest Information Update: 16 Jul 2019
At a glance
- Originator Argos Therapeutics Inc; Kirin Brewery
- Developer Argos Therapeutics Inc
- Class Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for research development in Infections in USA (Parenteral)
- 18 Sep 2014 Early research is ongoing for Cancer and Infections in USA